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lematic. There is no single ICD-9 code to identify FN; therefore an algorithm must be 
created to identify FN patients. Previously published algorithms are generally com-
prised of 3 main codes: (1) neutropenia (primary designation (ICD-9 code 288.0)) (2) 
fever (ICD-9 780.6) (3) infection. However, the primary designation of neutropenia 
is only used if there is no clear source of infection. Additionally, infection in the 
neutropenic cancer patient can often be difﬁcult to conﬁrm due to the lack of neutro-
phils and typical clinical symptoms and signs; the febrile response may also be blunted. 
Therefore, the FN algorithm may use neutropenia alone, likely identifying patients 
with neutropenia alone in addition to those with FN. In a study utilizing claims data, 
FN was deﬁned as primary or secondary diagnosis of neutropenia or infection during 
the ﬁrst chemotherapy course; 41% of cancer patient newly initiating chemotherapy 
were classiﬁed as having FN. When the FN deﬁnition was narrowed to primary or 
secondary diagnosis with neutropenia and either 1) fever or 2) infection 4.5% were 
classiﬁed as having FN; when the deﬁnition was broadened to diagnosis with neutro-
penia or fever or infection or a procedure code for infection treatment 64.7% were 
classiﬁed as having FN. There is a strong need to validate the coding associated with 
submitting medical claims for the treatment of FN in cancer patients receiving che-
motherapy in real-world practice in order to utilize claims data to investigate FN.
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OBJECTIVES: We introduce a method whereby the continuous enrollment require-
ment can be removed to increase the sample size and correct for incomplete informa-
tion with an advanced statistical technique. METHODS: The inverse probability 
weighted least squares model is used to estimate the outcomes from a sample that 
does not require continuous enrollment in the inclusion criteria. This method involves 
two steps: probabilities are estimated using a non-parametric approach, and standard 
errors of the outcomes regression are adjusted for the ﬁrst step estimation. RESULTS: 
To demonstrate the technique, we used U.S. claims data. Patients with incidents of 
cases of lung cancer were used. A total of 236 patients were identiﬁed without the 
continuous enrollment requirement of one year after diagnosis. With the continuous 
enrolment requirement, our sample size would be 87. Incomplete cases were more 
likely to have surgery and higher rates of comorbidities. R-squared increased 25% 
with the inverse probability weighted technique. Standard errors decreased with 35% 
and therefore improved the precision of our estimators. CONCLUSIONS: The con-
tinuous enrollment requirement does not have to be applied for pharmacoeconomical 
studies. Results might be biased if there are substantial differences between complete 
and incomplete observations. Even though there are no differences, removing this 
requirement increases the sample size and provides efﬁcient estimators, especially in 
rare events.
PCN159
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BACKGROUND: Hand-foot syndrome or Hand-Foot skin reaction is a common 
adverse effect of certain chemotherapy agents, such as capecitabine or pegylated 
doxorubicin, where it is estimated to occur in 50% of cases. OBJECTIVES: The aim 
of this study is to develop and validate a hand-foot syndrome-speciﬁc quality of life 
scale in order to be able to measure the impact of the condition on patients and 
secondly to be able to assess the value of certain speciﬁc treatments in this indication 
METHODS: The questionnaire was developed after conducting a series of structured 
interviews with patients with forms of hand-foot syndrome of varying severity, which 
yielded a detailed and rigorous collection of verbatim transcripts. The Pilot-Testing 
are realised. RESULTS: Thirty-one items were identiﬁed, and 14 items were selected 
as being relevant and non-overlapping after initial evaluation. The ﬁrst question in 
the HFS14 addresses which member is affected (hand, foot or both). The second 
question addresses the pain with three possible responses (very, moderately or not 
painful). The 14 items can be organised in 2 modules: the ﬁrst module more speciﬁcally 
assesses the handicap generated by involvement of the “feet” and the second assesses 
the handicap generated by involvement of the “hands”. CONCLUSIONS: The hand-
foot syndrome-speciﬁc HFS14 scale is easy to use and meets the requirements of a 
quality of life scale. This scale now needs to be tested in longitudinal studies (for 
example in clinical trials) to conﬁrm its ability to measure a change in status.
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PATIENT-REPORTED OUTCOMES SUPPORTING ONCOLOGY PRODUCT 
LABELING CLAIMS: TRENDS AND CHALLENGES
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The FDA has advocated the PRO Draft Guidance released in 2006 as the main vehicle 
for evaluating PRO and HRQOL claims in oncology product approvals. Additionally, 
FDA-afﬁliated researchers have identiﬁed factors inhibiting acceptance of HRQOL-
based claims for oncology product labels, including: trial design, missing data, multi-
plicity, and inconsistent ﬁndings of HRQOL data. The views of the FDA on PRO and 
HRQOL claims are extensive per its own guidance, which puts forth detailed, restric-
tive requirements on use. These matters clarify why the FDA has not yet allowed the 
utilization of PRO or HRQOL data as primary evidence to support an oncology 
product approval. In contrast, the EMEA since its establishment in 1995 has con-
ducted authorizations without an explicitly deﬁned approach for evaluating HRQOL 
and other PRO data. Further, a reﬂective paper released in 2005 offered only broad 
recommendations on HRQOL labeling claims. As a result, the importance of HRQOL 
or other PRO data in the review process is based more broadly on its relevance to a 
given drug and overall assessment of the study in the eyes of the reviewers. The varying 
approaches between the FDA and the EMEA partly stem from divergent underlying 
organizational characteristics. The FDA enforces laws regarding medical product 
quality. Alternatively, the EMEA serves as a coordinating body, leaving enforcement 
responsibility to member states. Consequently, the EMEA provides more generic 
advice, whereas the FDA insists on rigorous criteria for conceptual and study design 
issues surrounding PRO claims. Otherwise, the EMEA is more likely to accept use of 
well-established PRO and HRQOL measures, whereas the FDA is inclined to request 
new PRO measures that explicitly satisfy the agency’s most recent evaluative stan-
dards. Finally, the FDA places greater focus on symptom-based endpoints reﬂecting 
the direct consequences of treatment, whereas the EMEA is more willing to accept 
global HRQOL claims.
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OBJECTIVES: To describe the association between the three-year average glycosylated 
hemoglobin (A1C) and cardiovascular outcomes in adults with type 2 diabetes mellitus 
(T2DM). METHODS: In this nested case-control study, 245,346 adults (≥18 years) 
with T2DM were identiﬁed among members of Kaiser Permanente Southern Califor-
nia. Type 2 diabetic patients had at least two ICD-9 diagnosis codes for T2DM (250.
x0, 250.x2) and either A1C > 7.5% or prescriptions for hypoglycemic agents from 
2002–2007. Using hospital records and death certiﬁcates, cases were deﬁned as 
patients with a nonfatal MI, nonfatal stroke, or death due to cardiovascular (CV) 
causes (MI, stroke, heart failure, arrhythmia, sudden cardiac death) in the period 
2005–2007. Four controls from the T2DM pool were matched to each case based on 
age, sex and index date (date of the case deﬁning event). A conditional logistic regres-
sion model was used to estimate the odds-ratio (OR) of cardiovascular events compar-
ing patients with an average A1C ≤ 6 % and those with average A1C > 8% to patients 
with average A1C between 6–8%, considered ‘near A1C target’. A1C categories were 
assigned to each patient based on average A1C over the three years prior to the index 
date. RESULTS: A total of 44,628 controls were matched to 11,157 cases. After 
adjusting for CV related medications, comorbidities, and other confounders, patients 
with an average A1C ≤6% were 50% more likely to experience a CV event than the 
‘near A1C target’ T2DM patients (OR = 1.50, 95% CI 1.33–1.69, p < 0.0001). 
Patients with an average A1C > 8% experienced a 14% increase in odds of a CV event 
(OR = 1.14, 95% CI 1.03–1.26, p = 0.01). CONCLUSIONS: Compared to those with 
mean A1C levels between 6–8%, patients with T2DM who achieved mean A1C levels 
of ≤6% or failed to decrease their A1C below 8% over a 3-year period are at increased 
risk for cardiovascular events.
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OBJECTIVES: To assess the impact of oral antidiabetics agents on weight change in 
Type 2 Diabetes Mellitus (T2DM) patients age 65 years and older. METHODS: An 
electronic medical record, General Electric Centricity research database, containing 
the ambulatory health records of US patients was used to conduct a historical cohort 
study of the T2DM elderly patients identiﬁed by ICD-9 codes, OAD prescription or 
both. Six months of continuous OAD monotherapy activity was required, and study 
period included 395 days pre/210 days post from the index date. Two BMI/weight 
readings were mandated, at baseline, and follow up. Data were analyzed using 
ANOVA with Tukey test to correct for multiple comparisons. RESULTS: A total of 
2720 patients with a primary diagnosis of T2DM were included in the study. The 
overall mean age was 72.7 years. Statistical signiﬁcant differences between users of 
different OADs at baseline were found for diastolic blood pressure (p = 0.0009), and 
age (p < 0.001) The most prescribed OAD medications were metformin (58.9%), 
glipizide (14.52%) and glimepiride (7.76%).The overall mean change in A1C level 
was −0.92 (p < 0.001) units and statistically signiﬁcant differences were found when 
compared Metformin/Glipizide (mean difference 0.51320, 95% CI 0.06411–0.96230). 
The overall mean baseline BMI among all of the OAD groups was 29.08 kg/m². 
Signiﬁcant differences in BMI units change were found for meglitinide users, (-1.27), 
metformin users (-1.06), and the sulfonylureas (-0.14). An average of 3.97 lb weight 
loss for all of the OAD groups was found. Major weight loss was found in the Met-
formin group (-6.41lb), and the Sulfonylureas group reported the least weight loss 
(-0.89lb). CONCLUSIONS: An association was found between the OAD use and 
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change in weight measured by BMI and raw weight in elderly T2DM patients in a 
real-world setting. The likelihood of weight loss in OAD users was somewhat consis-
tent with the literature.
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OBJECTIVES: Renal insufﬁciency (RI), a common complication of type 2 diabetes 
mellitus (T2DM), is associated with increased morbidity, mortality and costs. Early 
and accurate detection of RI among patients with T2DM is essential in delaying or 
reducing these outcomes. Consensus guidelines advocate the use of estimated glomeru-
lar ﬁltration rate (eGFR) to assess renal function. The objective of this retrospective 
database analysis was to evaluate the prevalence of RI in a commercially-insured 
population with T2DM using ICD-9-CM codes and laboratory data from a large, 
national US health plan. METHODS: The study sample consisted of commercially-
insured health plan members ≥18 years of age with evidence of T2DM from 1/1/06–
12/31/07 and continuous enrollment for 12 months before and after identiﬁcation of 
T2DM. The prevalence of RI was determined by physician diagnosis using ICD-9-CM 
codes (“physician-diagnosed”), and eGFR calculation using serum creatinine (SCr), 
age and gender (“eGFR-diagnosed”). Approximately 26.8% of members had labora-
tory data (≥1 SCr value) after identiﬁcation; physician-diagnosed and eGFR-diagnosed 
RI prevalences were identiﬁed in this subset. RI was identiﬁed using the National 
Kidney Foundation (NKF) 5-stage classiﬁcation system and deﬁned as ≥ stage 2, or 
an eGFR of £89 ml/min. Comparisons between cohorts were made using chi-squares. 
RESULTS: Among over 13.7 million commercially-insured members within the data-
base, 664,619 (4.8%) had evidence of T2DM. The sample included 259,295 members 
after applying continuous enrollment and other study criteria, of which 20,914 (9.2%) 
had evidence of physician-diagnosed RI. Among the subset with laboratory data avail-
able (n = 69,439), 6,795 (9.8%) had physician-diagnosed RI while 17,981 (25.9%) 
had evidence of eGFR-diagnosed RI (p < 0.001). CONCLUSIONS: The prevalence of 
RI within a commercially-insured population with T2DM was signiﬁcantly higher 
using eGFR, the recommended method of estimating RI, than physician diagnosis of 
RI. It is likely that RI in the commercially-insured is under-estimated using diagnosis 
codes in claims data.
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OBJECTIVES: The objective of this study was to compare glycaemic control and 
insulin utilisation in insulin naïve patients with type 2 diabetes (T2D) after initiation 
on biphasic insulin aspart 30 (BIAsp) or biphasic human insulin 30 (BHI) METHODS: 
A retrospective cohort study was conducted using the IMS Disease Analyzer a UK 
primary care database. Study inclusion required subjects to be insulin naïve with at 
least one prescription for an oral anti-diabetic agent (proxy for T2D diagnosis), 12 
months history and follow up and treatment with either BIAsp or BHI. Patients with 
a diagnosis of type 1 diabetes were excluded. Glycemic control (HbA1c) was compared 
at baseline (-6 to 0 months) and at follow-up (+6 to 12 months). Average daily insulin 
dose (ADD) was compared at follow-up. Effect of age and sex as covariates on the 
difference in HbA1c and ADD between BIAsp and BHI was controlled for using 
ANOVA. RESULTS: Analyses were conducted on 630 BIAsp and 751 BHI patients 
on whom full data was available. The mean age for BIAsp patients was 61.6 years 
(59.7% men). For BHI, the mean age was 64.4 (51.9% men). From baseline to follow-
up, the mean HbA1c for BIAsp dropped from 9.95% to 8.16% (change = 1.79%) 
and for BHI the HbA1c dropped from 10.34% to 8.62% (change = 1.72%). The 
HbA1c difference was borderline signiﬁcant (p = 0.07). The ADD of BIAsp was 46.97 
insulin units whereas the BHI ADD was 63.28 IU (p < 0.01). CONCLUSIONS: In 
this large retrospective analysis in insulin naïve patients initiated on pre-mixed insulin 
there was a trend towards better glycaemic control for users of BIAp compared to 
BHI. Moreover, BIAsp was associated with a clinically relevant and statistically sig-
niﬁcantly lower ADD compared to BHI (p < 0.01). This has important implications 
for patient management and control of UK NHS costs.
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OBJECTIVES: As decision-makers and the citizens they serve demand stronger evi-
dence to support coverage, prioritization, and pricing, the need for relative effective-
ness research has come to the fore. Whilst it is well known and documented that 
differences in costing structures, practise patters and unit costs can lead to differences 
in cost effectiveness estimates for any given clinical effect, less is known about the 
heterogeneity of treatments and their utilization to demonstrate Relative Effectiveness 
(RE) among EU countries. This study investigated differences in treatment availability 
and utilization using recommendations from HTA agencies as a proxy. METHODS: 
HTA reports were searched using 7 European HTA agencies websites (i.e., NICE, 
SMC, IQWIG, HAS, CAHTA, CVZ, TLV with the following keywords: pioglitazone, 
rosiglitazone, sitagliptin, vildagliptin, exenatide, glargine, detemir, aspart, glulisine 
and lispro. Recommendation was classiﬁed in three categories: recommended, 
restricted recommended, and not recommended in relation to indication based on 
marketing authorisation. RESULTS: No HTA agency had similar recommendations 
for all treatments. IQWIG recommended none of the products assessed (8), while 
Sweden recommended 86% of the products assessed (7). NICE, SMC, HAS, CAHTA 
and CVZ assessed 18, 8, 18, 15, and 10 products, recommending 22%, 50%, 56%, 
13% and 0%, restricting 78%, 50%, 22%, 47% and 50% respectively. CONCLU-
SIONS: Large differences in recommendation of products among EU countries exist. 
As diabetes is a well established disease area, one would expect a more uniform 
armamentarium of recommended treatments. In light of the RE management plans, 
this research questions whether it is possible and desirable to develop a uniﬁed 
approach. Future research should focus on standardization of methods and address 
questions about acceptable methodology and its limitations.
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OBJECTIVES: The objective of the study was to compare real-life glycaemic control, 
insulin utilisation and body weight in patients with type 2 diabetes initiated on insulin 
detemir (IDet) or insulin glargine (IGlar) and to discuss the results against treatment 
guidelines. METHODS: Patients with a history of oral anti-diabetic use starting treat-
ment with IDet or IGlar from 2004 through 2006 were included in a retrospective 
cohort study using the Dutch PHARMO data network. Glycaemic control (HbA1c < 
7%) and daily insulin dose during unchanged insulin treatment up to 1 year of follow-
up were compared between IDet and IGlar users using multivariate regression analysis 
adjusted for age, gender, propensity scores, baseline HbA1c and basal-bolus therapy. 
The observed results are discussed in context of European diabetes guidelines. 
RESULTS: A similar (p = 0.44) drop in HbA1c (from 8.6% to 7.5%) was observed 
for both IDet (n = 199) and IGlar (n = 479). Few patients were at goal at baseline 
(15.6% with IDet and 12.1% with IGlar). A similar proportion were at goal at follow-
up (38.7% with IDet and 33.4% with IGlar) (adjusted OR 1.06; 95% CI 0.74:1.53). 
The average daily dose was similar at 29 IU/day (adjusted mean difference 0.2; 95% 
CI -2.9:3.2). Median weight loss was 1 kg among IDet users and 0 kg among IGlar 
users, but this was not statistically tested due to low patient numbers. CONCLU-
SIONS: There was no signiﬁcant difference between users of IDet and IGlar with 
respect to glycaemic control and insulin dose in a real-life setting in the The Nether-
lands. However, compared with treatment guidelines, the results showed few patients 
treated to target, which may indicate that basal insulin analogues are not titrated 
intensive enough or that rapid-acting insulin should be added to improve glycaemic 
control.
PDB8
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OBJECTIVES: Studies suggest that premixed insulin analogues may improve the 
balance between glycaemic control and hypoglycaemia compared with human pre-
mixed insulin in type 2 diabetes (T2D) patients. This study aimed to observe prescrip-
tion patterns of premixed insulin analogues compared to human premixed insulin 
among T2D patients. METHODS: Data for T2D patients starting premixed insulin 
in the period 2004–2006 were extracted from the Dutch PHARMO database. Patients 
were categorized into insulin naïve and prior insulin users. The proportion of patients 
changing treatment (discontinuing, adding fast-acting insulin or switching treatment) 
within one year was determined. Data was analyzed using Chi-Square tests for cate-
gorical data and t-tests for continuous data. RESULTS: The study included 3530 
patients initiated on premixed insulin, of which 2324 (65.8%) were insulin naïve. 
Overall, 2134 (60.5%) started on analogues; the proportion of prescribed analogue 
insulin was greater among prior insulin users (812 of 1206 = 67.3%) vs. naïve users 
(1322 of 2324 = 56.9%). Patient characteristics did not differ between human insulin 
and analogue users, except from baseline HbA1c: in the group of prior users (1206 / 
34.2%), a signiﬁcant difference in baseline HbA1c was observed between those using 
human premixed insulin (8.5%) and premixed analogue (8.0%, p < 0.001). Within 
one year, 44.1% of human premixed users and 33.5% of premixed analogue users 
changed treatment. Among human premixed users 20.1% discontinued treatment (230 
days), 6.5% added fast-acting insulin to their therapy (114 days), and 17.6% switched 
treatment (143 days); among premixed analogue users 14.9% discontinued treatment 
(245 days), 5.8% added fast-acting insulin (137 days), and 12.9% switched treatment 
